银屑病合并代谢性疾病发病机制的研究进展

doi:10.3760/cma.j.issn.1007-1245.2023.09.002

摘要/Abstract

摘要：

银屑病是一种常见的由免疫介导的慢性炎症性皮肤病，其发病机制与遗传、免疫、感染、环境等多种因素有关。近年来，银屑病患者合并代谢性疾病的发病率显著增高，大量国内外研究表明，银屑病与代谢性疾病之间可能存在着共同的发病机制，尤其包括炎症因子、脂肪因子、易感基因等的参与。深入了解银屑病合并代谢性疾病的发病机制对于银屑病的治疗与合并症的预防具有重要的指导意义。

关键词:

银屑病, 代谢性疾病, 共病, 炎症因子, 脂肪因子

Abstract:

Psoriasis is a common immune-mediated chronic inflammatory skin disease, and its pathogenesis is related to genetic, immune, infectious, environmental, and other factors. In recent years, the incidence of psoriasis complicated with metabolic diseases has increased significantly. A large number of domestic and foreign studies have shown that there may be common pathogenesis between psoriasis and metabolic diseases, especially involving inflammatory factors, adipokines, and susceptibility genes. A thorough understanding of pathogenesis of psoriasis complicated with metabolic diseases is of great significance for the treatment of psoriasis and the prevention of its complications.

Key words:

Psoriasis, Metabolic diseases, Comorbidity, Inflammatory factors, Adipokines

解胜华吴雪梅张玉杰.

银屑病合并代谢性疾病发病机制的研究进展 [J]. 国际医药卫生导报, 2023, 29(9): 1189-1192.

Xie Shenghua, Wu Xuemei, Zhang Yujie.

Advances on pathogenesis of psoriasis complicated with metabolic diseases [J]. International Medicine and Health Guidance News, 2023, 29(9): 1189-1192.

参考文献

[1] Korman NJ. Management of psoriasis as a systemic disease: what is the evidence?[J]. Br J Dermatol, 2020, 182(4):840-848. DOI: 10.1111/bjd.18245.
[2] Hao Y, Zhu YJ, Zou S, et al. Metabolic syndrome and psoriasis: mechanisms and future directions[J]. Front Immunol, 2021, 12:711060. DOI: 10.3389/fimmu.2021. 711060.
[3] Lee SH, Park SY, Choi CS. Insulin resistance: from mechanisms to therapeutic strategies[J]. Diabetes Metab J, 2022, 46(1):15-37. DOI: 10.4093/dmj.2021.0280.
[4] Pérez-García A, Torrecilla-Parra M, Fernández-de Frutos M, et al. Posttranscriptional regulation of insulin resistance: implications for metabolic diseases[J]. Biomolecules, 2022, 12(2):208. DOI: 10.3390/biom12020208.
[5] Boehncke S, Thaci D, Beschmann H, et al. Psoriasis patients show signs of insulin resistance[J]. Br J Dermatol, 2007, 157(6):1249-1251. DOI: 10.1111/j.1365-2133. 2007.08190.x.
[6] Gyldenløve M, Storgaard H, Holst JJ, et al. Patients with psoriasis are insulin resistant[J]. J Am Acad Dermatol, 2015, 72(4):599-605. DOI: 10.1016/j.jaad.2015.01.004.
[7] Caroppo F, Galderisi A, Ventura L, et al. Metabolic syndrome and insulin resistance in pre-pubertal children with psoriasis[J]. Eur J Pediatr, 2021, 180(6):1739-1745. DOI: 10.1007/s00431-020-03924-w.
[8] Buerger C, Richter B, Woth K, et al. Interleukin-1β interferes with epidermal homeostasis through induction of insulin resistance: implications for psoriasis pathogenesis[J]. J Invest Dermatol, 2012, 132(9):2206-2214. DOI: 10.1038/jid.2012.123.
[9] Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease[J]. Cytokine Growth Factor Rev, 2002, 13(4-5):357-368. DOI: 10.1016/s1359-6101(02)00027-8.
[10] Kang S, Narazaki M, Metwally H, et al. Historical overview of the interleukin-6 family cytokine[J]. J Exp Med, 2020, 217(5):e20190347. DOI: 10.1084/jem.20190347.
[11] Miao X, Xiang Y, Mao W, et al. TRIM27 promotes IL-6-induced proliferation and inflammation factor production by activating STAT3 signaling in HaCaT cells[J]. Am J Physiol Cell Physiol, 2020, 318(2):C272-C281. DOI: 10.1152/ajpcell.00314.2019.
[12] Kaur S, Zilmer K, Kairane C, et al. Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis[J]. Br J Dermatol, 2008, 159(6):1364-1367. DOI: 10.1111/j.1365-2133.2008.08759.x.
[13] 史雅琼,马建伟,庞晓文,等.银屑病合并代谢综合征患者血hs-CRP、IL-6水平及理化指标变化的意义[J].解放军医药杂志,2015,27(9):21-23. DOI:10.3969/j.issn.2095- 140X.2015.08.005.
[14] Błaszczyk M, Gajewska M, Dymowska M, et al. Interleukin-6 mimics insulin-dependent cellular distribution of some cytoskeletal proteins and Glut4 transporter without effect on glucose uptake in 3T3-L1 adipocytes[J]. Histochem Cell Biol, 2022, 157(5):525-546. DOI: 10.1007/s00418-022-02091-3.
[15] Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1β secretion[J]. Cytokine Growth Factor Rev, 2011, 22(4):189-195. DOI: 10.1016/j.cytogfr.2011. 10.001.
[16] Tang L, Zhou F. Inflammasomes in common immune-related skin diseases[J]. Front Immunol, 2020, 11:882. DOI: 10.3389/fimmu.2020.00882.
[17] Jager J, Grémeaux T, Cormont M, et al. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression[J]. Endocrinology, 2007, 148(1):241-251. DOI: 10.1210/en.2006-0692.
[18] Johnston A, Arnadottir S, Gudjonsson JE, et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation[J]. Br J Dermatol, 2008, 159(2):342-350. DOI: 10.1111/j.1365-2133.2008.08655.x.
[19] Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis[J]. Lancet, 2007, 370(9583):263-271. DOI: 10.1016/S0140-6736(07)61128-3.
[20] Yaribeygi H, Farrokhi FR, Butler AE, et al. Insulin resistance: review of the underlying molecular mechanisms[J]. J Cell Physiol, 2019, 234(6):8152-8161. DOI: 10.1002/jcp.27603.
[21] Botelho KP, Pontes MAA, Rodrigues CEM, et al. Prevalence of metabolic syndrome among patients with psoriasis treated with TNF inhibitors and the effects of anti-TNF therapy on their lipid profile: a prospective cohort study[J]. Metab Syndr Relat Disord, 2020, 18(3):154-160. DOI: 10.1089/met.2019.0092.
[22] Guzik TJ, Mangalat D, Korbut R. Adipocytokines - novel link between inflammation and vascular function? [J]. J Physiol Pharmacol, 2006, 57(4):505-528.
[23] Lynch M, Ahern T, Sweeney CM, et al. Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction[J]. Int J Dermatol, 2017, 56(11):1103-1118. DOI: 10.1111/ijd.13699.
[24] Blüher M. Adipokines - removing road blocks to obesity and diabetes therapy[J]. Mol Metab, 2014, 3(3):230-240. DOI: 10.1016/j.molmet.2014.01.005.
[25] La Cava A. Leptin in inflammation and autoimmunity[J]. Cytokine, 2017, 98:51-58. DOI: 10.1016/j.cyto.2016. 10.011.
[26] Chen YJ, Wu CY, Shen JL, et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome[J]. Arch Dermatol, 2008, 144(12):1571-1575. DOI: 10.1001/archderm.144.12.1571.
[27] Sudan SK, Deshmukh SK, Poosarla T, et al. Resistin: an inflammatory cytokine with multi-faceted roles in cancer[J]. Biochim Biophys Acta Rev Cancer, 2020, 1874(2):188419. DOI: 10.1016/j.bbcan.2020.188419.
[28] Wolk K, Sabat R. Adipokines in psoriasis: an important link between skin inflammation and metabolic alterations[J]. Rev Endocr Metab Disord, 2016, 17(3):305-317. DOI: 10.1007/s11154-016-9381-0.
[29] Kyriakou A, Patsatsi A, Sotiriadis D, et al. Serum leptin, resistin, and adiponectin concentrations in psoriasis: a meta-analysis of observational studies[J]. Dermatology, 2017, 233(5):378-389. DOI: 10.1159/000481882.
[30] Hetta HF, Ez-Eldeen ME, Mohamed GA, et al. Visfatin serum levels in obese type 2 diabetic patients: relation to proinflammatory cytokines and insulin resistance[J]. Egypt J Immunol, 2018, 25(2):141-151.
[31] Buechler C, Feder S, Haberl EM, et al. Chemerin isoforms and activity in obesity[J]. Int J Mol Sci, 2019, 20(5):1128. DOI: 10.3390/ijms20051128.
[32] Chyl-Surdacka KM, Bartosińska J, Kowal M, et al. Assessment of visfatin concentrations in the serum of male psoriatic patients in relation to metabolic abnormalities[J]. Adv Clin Exp Med, 2020, 29(1):79-84. DOI: 10.17219/acem/111820.
[33] Gisondi P, Lora V, Bonauguri C, et al. Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab[J]. Br J Dermatol, 2013, 168(4):749-755. DOI: 10.1111/bjd.12118.
[34] Straub LG, Scherer PE. Metabolic messengers: adiponectin[J]. Nat Metab, 2019, 1(3):334-339. DOI: 10.1038/s42255-019-0041-z.
[35] 陈倩楠,伍丽,朱益民,等.肥胖者血清脂联素水平与代谢状况的关系[J].华中科技大学学报(医学版),2021,50(6):778-782. DOI:10.3870/j.issn.1672-0741.2021.06.017.
[36] Ruiyang B, Panayi A, Ruifang W, et al. Adiponectin in psoriasis and its comorbidities: a review[J]. Lipids Health Dis, 2021, 20(1):87. DOI: 10.1186/s12944-021-01510-z.
[37] Gerdes S, Pinter A, Biermann M, et al. Adiponectin levels in a large pooled plaque psoriasis study population[J]. J Dermatolog Treat, 2020, 31(5):531-534. DOI: 10.1080/09546634.2019.1621979.
[38] Chan WSA, Liew CF, Theng CTS, et al. Serum adiponectin levels and their association with cardiometabolic risk factors in patients with psoriasis[J]. Cureus, 2020, 12(5):e8128. DOI: 10.7759/cureus.8128.
[39] Ismail SA, Mohamed SA. Serum levels of visfatin and omentin-1 in patients with psoriasis and their relation to disease severity[J]. Br J Dermatol, 2012, 167(2):436-439. DOI: 10.1111/j.1365-2133.2012.10980.x.
[40] Dağdelen D, Karadag AS, Kasapoğlu E, et al. Correlation of metabolic syndrome with serum omentin-1 and visfatin levels and disease severity in psoriasis and psoriatic arthritis[J]. Dermatol Ther, 2020, 33(6):e14378. DOI: 10.1111/dth.14378.
[41] 戴前梅,陈朋,高金平.银屑病患者血清网膜素-1水平及其与代谢综合征的相关性[J].中国皮肤性病学杂志,2022,36(2):155-160. DOI:10.13735/j.cjdv.1001-7089. 202107147.
[42] Ogawa K, Okada Y. The current landscape of psoriasis genetics in 2020[J]. J Dermatol Sci, 2020, 99(1):2-8. DOI: 10.1016/j.jdermsci.2020.05.008.
[43] Wolf N, Quaranta M, Prescott NJ, et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease[J]. J Med Genet, 2008, 45(2):114-116. DOI: 10.1136/jmg.2007.053595.
[44] Wang H, Wang Z, Rani PL, et al. Identification of PTPN22, ST6GAL1 and JAZF1 as psoriasis risk genes demonstrates shared pathogenesis between psoriasis and diabetes[J]. Exp Dermatol, 2017, 26(11):1112-1117. DOI: 10.1111/exd.13393.
[45] Tupikowska-Marzec M, Kolačkov K, Zdrojowy-Wełna A, et al. The influence of FTO polymorphism rs9939609 on obesity, some clinical features, and disturbance of carbohydrate metabolism in patients with psoriasis[J]. Biomed Res Int, 2019, 2019:7304345. DOI: 10.1155/2019/7304345.